Altered specificity of alloreactive cardiac graft-infiltrating cells by prophylactic treatment with OKT3 or horse antilymphocyte globulin

Transplantation. 1993 Jan;55(1):154-8. doi: 10.1097/00007890-199301000-00028.

Abstract

Graft-infiltrating lymphocytes from patients who were prophylactically treated with OKT3 or horse antilymphocyte globulin (H-ALG) were found to have different specificity patterns from those in the control group that received cyclosporine from the day of transplantation. This prophylactic treatment led to a significant decrease of the HLA-DR-directed cytotoxicity, while the cytolytic response against HLA-class I mismatches was hardly affected. In H-ALG patients without rejection, the percentages of class I-reactive cultures were found to be lower than in the other treatment groups, which was mainly due to a lower percentage of HLA-B--reactive cultures. In CsA and OKT3 patients, cytotoxic T cells were rather directed to HLA-B mismatches than to HLA-A antigens, while in H-ALG patients no difference in HLA-A and B-directed cytotoxicity was found. Our data suggest that OKT3 and H-ALG influence the specificity of the T cell allorepertoire, resulting in a decreased frequency of class II-specific cytotoxic T cells after transplantation. H-ALG also has a downregulating influence on the CTL response against HLA class I (HLA-B) antigens. In some patients a fast regeneration of these cells occurs, which results in a higher rejection incidence during the first posttransplant year.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antilymphocyte Serum / therapeutic use*
  • Biopsy
  • Cyclosporine / therapeutic use*
  • Endocardium / pathology
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • HLA-A Antigens / immunology
  • HLA-B Antigens / immunology
  • Heart Transplantation / immunology*
  • Histocompatibility / immunology
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Muromonab-CD3 / therapeutic use*
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Antilymphocyte Serum
  • HLA-A Antigens
  • HLA-B Antigens
  • Histocompatibility Antigens Class I
  • Muromonab-CD3
  • Cyclosporine